Literature DB >> 3007715

Hemophiliac immunodeficiency: influence of exposure to factor VIII concentrate, LAV/HTLV-III, and herpesviruses.

J L Sullivan, F E Brewster, D B Brettler, A D Forsberg, S H Cheeseman, K S Byron, S M Baker, D L Willitts, R A Lew, P H Levine.   

Abstract

The relationship between hemophiliac immunodeficiency and exposures to factor VIII concentrate, LAV/HTLV-III retrovirus, and infection with Epstein-Barr virus and cytomegalovirus was examined. Exposure to factor VIII concentrate was significantly correlated with decreased percentages of T helper/inducer cells, decreased T helper/suppressor cell ratios, and decreased proliferative responses to plant mitogens. LAV/HTLV-III seropositivity was the primary predictor of increased percentages of HLA-DR-bearing mononuclear cells and decreased proliferative responses to pokeweed mitogen. Epstein-Barr virus and cytomegalovirus infections acted in a synergistic manner with LAV/HTLV-III to produce immunoregulatory defects. Increased percentages of T suppressor cells and decreased delayed cutaneous hypersensitivity skin test responses were observed in LAV/HTLV-III seropositive hemophiliacs infected with Epstein-Barr or cytomegalovirus. We conclude that hemophiliacs receiving commercial factor VIII concentrate experience several stepwise incremental insults to the immune system: alloantigens in factor VIII concentrate, LAV/HTLV-III infections, and herpesvirus infections.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3007715     DOI: 10.1016/s0022-3476(86)80823-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  13 in total

1.  Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates.

Authors:  C Wadsworth; L A Hanson; H Kjellman; T Söderström; M Blombäck
Journal:  Blut       Date:  1989-03

2.  Survival analysis of hemophilia-associated AIDS cases in the US.

Authors:  J K Stehr-Green; R C Holman; M A Mahoney
Journal:  Am J Public Health       Date:  1989-07       Impact factor: 9.308

3.  Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera.

Authors:  R A Koup; J L Sullivan; P H Levine; F Brewster; A Mahr; G Mazzara; S McKenzie; D Panicali
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  HIV infection in haemophilia--a European cohort.

Authors:  A Aronstam; B Congard; D I Evans; C F Gazengel; U Herberg; F G Hill; P M Jones; R Ljung; E P Mauser-Bunschoten; E Scheibel
Journal:  Arch Dis Child       Date:  1993-04       Impact factor: 3.791

5.  HIV-1 infection in a cohort of haemophilic patients.

Authors:  N Wagner; R Bialek; H Radinger; M Becker; K E Schneweis; H H Brackmann; D Niese
Journal:  Arch Dis Child       Date:  1990-12       Impact factor: 3.791

Review 6.  Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation.

Authors:  P H Duesberg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  Human immunodeficiency virus infection in multi-transfused patients with thalassaemia major.

Authors:  P E Manconi; C Dessí; G Sanna; F Argiolu; P Pellegrini-Bettoli; R Piro; O Masotti; A Cao
Journal:  Eur J Pediatr       Date:  1988-04       Impact factor: 3.183

8.  Limiting dilution analysis of cytotoxic T lymphocytes to human immunodeficiency virus gag antigens in infected persons: in vitro quantitation of effector cell populations with p17 and p24 specificities.

Authors:  R A Koup; C A Pikora; K Luzuriaga; D B Brettler; E S Day; G P Mazzara; J L Sullivan
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

Review 9.  Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV.

Authors:  P H Duesberg
Journal:  Genetica       Date:  1995       Impact factor: 1.082

10.  A rare case of acute lymphoblastic leukaemia with hemophilia A.

Authors:  Rahul Sinha; Kirandeep Sodhi; Biju John; Daljit Singh
Journal:  Ital J Pediatr       Date:  2009-12-11       Impact factor: 2.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.